European Medicines Agency recommends approval of new medicine for Cushing’s disease

New somatostatin analogue recommended to be first approved medical therapy for rare hormonal disorder

 

London, UK (January 20, 2012) – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of a new medicine intended for the treatment of Cushing’s disease in patients who cannot have surgery or for whom surgery has not been successful.

 

Cushing’s disease is a very rare, debilitating and life-threatening disease, where a small tumour of the pituitary (an endocrine gland) makes too much of the hormone adrenocorticotrophin (ACTH), which in turn stimulates the adrenal glands to both grow and release excessive amounts of cortisol in the blood. This causes a set of symptoms including weight gain (particularly in the face and neck), easy bruising, excessive growth of coarse hair on the face, weakening of the muscles and bones, and high blood pressure. Cushing’s disease is estimated to affect approximately 0.4 in 10,000 people in the European Union. This is equivalent to a total of around 20,000 people.

 

The first-line therapy for patients with Cushing’s disease is surgical removal of the tumour. However, for patients who cannot be cured by surgery there are currently no approved medical treatments. A number of medicines are being used off-label to treat the disease, but the available data on their safety and efficacy is limited.

 

The recommendation to approve Signifor (pasireotide) for the treatment of Cushing’s disease is the first step in making a medicine available to European patients that has been studied in the indication and for which doctors and patients are provided with specific information about its use.

 

Signifor is a somatostatin analogue. It attaches to somatostatin receptors, which are found in large numbers in tumour cells of the pituitary gland. By attaching to these receptors, Signifor blocks the release of ACTH. This results in the reduction of cortisol levels, helping to relieve the symptoms of Cushing’s disease.

 

In clinical trials, Signifor was shown to reduce the levels of cortisol in the urine by at least 50% in 41% of patients treated with a 900μg dose and in 34% of patients treated with a 600μg dose. In terms of safety, the CHMP noted that Signifor’s safety profile is similar to that of other somatostatin analogues, which have been approved for many years in the EU. The product information specifically advises doctors to monitor patients for liver and heart problems. With these precautions in place, the CHMP concluded that the benefits of Signifor outweigh its risks as a second-line treatment for patients with Cushing’s disease and recommended its authorisation in the EU.

 

 

Notes

 

  • The Committee’s recommendation has now been forwarded to the European Commission for the adoption of an opinion.
  • Pasireotide was designated as an orphan medicine on 8 October 2009.

 


 

European Medicines Agency (EMA), 20.01.2012 (tB).

MEDICAL NEWS

Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…
Starting the day off with chocolate could have unexpected benefits
Better mental health supports for nurses needed, study finds

SCHMERZ PAINCARE

Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…
Jedes vierte Kind wünscht bessere Schmerzbehandlung
Lebensqualität von Patienten in der dauerhaften Schmerztherapie mit Opioiden verbessern

DIABETES

Bundestag berät über DMP Adipositas: DDG begrüßt dies als Teil…
Mit der Smartwatch Insulinbildung steuern
Verbände fordern bessere Ausbildung und Honorierung von Pflegekräften für Menschen…
Minimalinvasive Geräte warnen ungenügend vor Unterzuckerung
Typ-1-Diabetes und Hashimoto-Thyreoiditis treten häufig gemeinsam auf

ERNÄHRUNG

Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen
Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren

ONKOLOGIE

Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!
Deutsch-dänisches Interreg-Projekt: Grenzübergreifende Fortbildungskurse in der onkologischen Pflege
Sotorasib: Neues Medikament macht Lungenkrebs-Patienten Hoffnung

MULTIPLE SKLEROSE

NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen
Verzögerte Verfügbarkeit von Ofatumumab (Kesimpta®)
Neuer Biomarker bei Multipler Sklerose ermöglicht frühe Risikoeinschätzung und gezielte…
Multiple Sklerose beginnt oft lange vor der Diagnose
Goldstandard für Versorgung bei Multipler Sklerose

PARKINSON

Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…
Gemeinsam gegen Parkinson: bessere Therapie durch multidisziplinäre Versorgung